| 產(chǎn)品編號(hào) | bs-0528R-HRP |
| 英文名稱(chēng)1 | Rabbit Anti-CD24/HRP Conjugated antibody |
| 中文名稱(chēng) | 辣根過(guò)氧化物酶標(biāo)記的CD24抗體 |
| 別 名 | CD 24; CD24; CD24 antigen (small cell lung carcinoma cluster 4 antigen); CD24 antigen; CD24 molecule; CD24_HUMAN; CD24A; GPI linked surface mucin; Heat stable antigen; HSA; Nectadrin; Signal transducer CD24; Small cell lung carcinoma cluster 4 antigen; Cd24; Cd24a; Ly-52. |
| 規(guī)格價(jià)格 | 100ul/2980元 購(gòu)買(mǎi) 大包裝/詢(xún)價(jià) |
| 說(shuō) 明 書(shū) | 100ul |
| 研究領(lǐng)域 | 腫瘤 細(xì)胞生物 免疫學(xué) 神經(jīng)生物學(xué) 干細(xì)胞 細(xì)胞粘附分子 細(xì)胞表面分子 糖蛋白 t-淋巴細(xì)胞 b-淋巴細(xì)胞 骨髓細(xì)胞 |
| 抗體來(lái)源 | Rabbit |
| 克隆類(lèi)型 | Polyclonal |
| 交叉反應(yīng) | Human, Rat, (predicted: Mouse, ) |
| 產(chǎn)品應(yīng)用 | WB=1:500-2000 ELISA=1:100-1000
not yet tested in other applications. optimal dilutions/concentrations should be determined by the end user. |
| 分 子 量 | 8kDa |
| 性 狀 | Lyophilized or Liquid |
| 濃 度 | 1mg/ml |
| 免 疫 原 | KLH conjugated synthetic peptide derived from human CD24 Propeptide (60-80) |
| 亞 型 | IgG |
| 純化方法 | affinity purified by Protein A |
| 儲(chǔ) 存 液 | 0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. |
| 保存條件 | Store at -20 °C for one year. Avoid repeated freeze/thaw cycles. The lyophilized antibody is stable at room temperature for at least one month and for greater than a year when kept at -20°C. When reconstituted in sterile pH 7.4 0.01M PBS or diluent of antibody the antibody is stable for at least two weeks at 2-4 °C. |
| 產(chǎn)品介紹 |
background: This gene encodes a sialoglycoprotein that is expressed on mature granulocytes and in many B cells. The encoded protein is anchored via a glycosyl phosphatidylinositol (GPI) link to the cell surface. [provided by RefSeq, Jul 2008]. Function: Modulates B-cell activation responses. Signaling could be triggered by the binding of a lectin-like ligand to the CD24 carbohydrates, and transduced by the release of second messengers derived from the GPI-anchor. Promotes AG-dependent proliferation of B-cells, and prevents their terminal differentiation into antibody-forming cells. Subunit: Belongs to the CD24 family. Subcellular Location: Cell membrane. Tissue Specificity: B-cells. Expressed in a number of B-cell lines including P32/SH and Namalwa. Expressed in erythroleukemia cell and small cell lung carcinoma cell lines. Also expressed on the surface of T-cells. Post-translational modifications: Extensively O-glycosylated. DISEASE: Genetic variations in CD24 are associated with susceptibility to multiple sclerosis (MS). A multifactorial, inflammatory, demyelinating disease of the central nervous system. Sclerotic lesions are characterized by perivascular infiltration of monocytes and lymphocytes and appear as indurated areas in pathologic specimens (sclerosis in plaques). The pathological mechanism is regarded as an autoimmune attack of the myelin sheat, mediated by both cellular and humoral immunity. Clinical manifestations include visual loss, extra-ocular movement disorders, paresthesias, loss of sensation, weakness, dysarthria, spasticity, ataxia and bladder dysfunction. Genetic and environmental factors influence susceptibility to the disease. Note=Polymorphisms in CD24 may act as a genetic modifier for susceptibility and progression of MS in some populations, perhaps by affecting the efficiency of CD24 expression on the cell surface. Similarity: Belongs to the CD24 family. Database links: Entrez Gene: 100133941 Human Entrez Gene: 12484 Mouse Omim: 600074 Human SwissProt: P25063 Human SwissProt: P24807 Mouse Unigene: 644105 Human Unigene: 721443 Human Unigene: 29742 Mouse Unigene: 6007 Rat Important Note: This product as supplied is intended for research use only, not for use in human, therapeutic or diagnostic applications. 神經(jīng)干細(xì)胞標(biāo)志物 腫瘤標(biāo)志物 CD24是一種低分子質(zhì)量高度糖基化的黏附分子, 主要表達(dá)在造血系統(tǒng). 最近研究表明, 在造血系統(tǒng)腫瘤和一些器官的實(shí)體瘤表面可見(jiàn)CD24高表達(dá)。 近幾年很多學(xué)者認(rèn)為：CD24在前列腺癌、非小細(xì)胞肺癌、鼻咽癌、原發(fā)性肝細(xì)胞癌、膽管細(xì)胞癌、麥克爾細(xì)胞癌、神經(jīng)源性腫瘤、胰腺癌、胃癌、結(jié)腸癌、腎細(xì)胞癌、B細(xì)胞淋巴瘤、乳腺癌等腫瘤組織中表達(dá)增強(qiáng), 且和腫瘤侵襲轉(zhuǎn)移、復(fù)發(fā)和預(yù)后相關(guān)。 |
